ѻý

<ѻý class="page-title">Meeting Coverage

ACR Expert Roundtable

<ѻý class="page-description">Expert Roundtable from the American College of Rheumatology
Using Baseline Markers to Predict Response in Psoriatic Arthritis

More biomarker research is needed, but new study is a good start

image
<ѻý class="section_title">Latest ACR Expert Roundtable Meeting Coverage
Improvements With Guselkumab in Psoriatic Arthritis Seen Across All MDA Domains

Experts discuss importance of both physician- and patient-reported domains

December 6, 2023
New Data on Bimekizumab in Psoriatic Arthritis

Roundtable of experts weigh in on "unprecedented" efficacy, and safety issues

November 29, 2023
New Data on TYK2 Inhibitors for Psoriasis, Psoriatic Arthritis

Favorable results with TAK-279 and deucravacitinib in studies at ACR

November 22, 2023
Deucravacitinib Remains Safe, Effective Through Week 52 in Psoriatic Arthritis

Andrew Blauvelt, MD, leads a roundtable discussion with Melinda Gooderham, MSc, MD, and Neil Korman, MD

December 13, 2022
Upadacitinib Versus Adalimumab in Psoriatic Arthritis

Andrew Blauvelt, MD, leads a discussion with Melinda Gooderham, MD, MSc, and Neil Korman, MD, PhD

December 6, 2022
IL-23 Inhibitors for Psoriatic Arthritis

An expert roundtable discussion on guselkumab and risankizumab

November 29, 2022
Safety and Efficacy of IL-17 Blockers for Psoriatic Arthritis

Andrew Blauvelt, MD, leads a discussion with Melinda Gooderham, MD, MSc, and Neil Korman, MD, PhD

November 22, 2022
Leveraging Digital Tech and Shared Decision-Making in PsA Care

Our expert roundtable discusses patient-physician discordance and the need for tracking PROs

December 15, 2021
What Factors Predict a Shorter Transition From Psoriasis to PsA?

Our expert roundtable looks at possible clinical/demographic predictors, or biomarkers

December 8, 2021
TYK2 Inhibitors Show Efficacy in Psoriatic Arthritis

Our expert roundtable discusses promising results from two studies on TYK2/JAK1 inhibitors

December 1, 2021
Exploring the Potential of Guselkumab in Psoriatic Arthritis

Our expert roundtable discusses the long-term efficacy and safety of the IL-23 inhibitor

November 24, 2021
<ѻý class="section_title">Videos
ACR
November 2023
EULAR
June 2024